Thomson Reuters to divest healthcare unit

Mary Stevens | | Health Exec | Economics
Thomson Reuters is divesting its healthcare business, which provides data, analytics and performance benchmarking technologies and services to companies, government agencies and healthcare professionals, by the end of the year.

Thomson Reuters Healthcare is a unit of the company’s Healthcare & Science segment. The unit—which had revenues of approximately $450 million in 2010—is expected “to attract substantial demand from buyers as we sell into a consolidating market,” the New York City-based company predicted.

The decision to sell the healthcare unit was due to its lack of integration with the global scale of other units, and “the expected proceeds from a sale into a consolidating market could be better applied elsewhere in our portfolio,” stated Thomas H. Glocer, CEO of Thomson Reuters.

Following adjustment for this divestiture by removing the healthcare unit’s results from ongoing businesses, no material impact is expected to the company’s previously announced 2011 outlook, according to the company.

Morgan Stanley and Allen are acting as financial advisors to Thomson Reuters for the proposed divestiture.

Mary Stevens

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.